Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
Altamira Therapeutics (OTCQB:CYTOF) has entered into a collaboration agreement with an undisclosed company to evaluate its CycloPhore™ platform for circular RNA payload delivery. The partnership involves testing CycloPhore nanoparticles both in vitro and in vivo, with the partner having an option to negotiate a license agreement for developing and commercializing circRNA nanoparticles with their proprietary RNA payload.
The collaboration marks the first partnership for Altamira's recently launched CycloPhore platform, specifically designed for circular RNA delivery. According to COO Covadonga Pañeda, circular mRNA could enable lower dosing and less frequent administrations compared to linear mRNA, representing a promising approach in RNA drug development.
Altamira Therapeutics (OTCQB:CYTOF) ha stipulato un accordo di collaborazione con un'azienda non divulgata per valutare la sua piattaforma CycloPhore™ per la somministrazione di carichi utili di RNA circolare. La partnership prevede test in vitro e in vivo dei nanoparticelle CycloPhore, con l'opzione per il partner di negoziare un accordo di licenza per lo sviluppo e la commercializzazione di nanoparticelle circRNA con il loro carico utile RNA proprietario.
Questa collaborazione rappresenta la prima partnership per la piattaforma CycloPhore di recente lancio di Altamira, progettata specificamente per la somministrazione di RNA circolare. Secondo la COO Covadonga Pañeda, l'mRNA circolare potrebbe permettere dosaggi più bassi e somministrazioni meno frequenti rispetto all'mRNA lineare, rappresentando un approccio promettente nello sviluppo di farmaci a base di RNA.
Altamira Therapeutics (OTCQB:CYTOF) ha firmado un acuerdo de colaboración con una empresa no revelada para evaluar su plataforma CycloPhore™ para la entrega de cargas útiles de ARN circular. La asociación implica probar las nanopartículas CycloPhore tanto in vitro como in vivo, con la opción para el socio de negociar un acuerdo de licencia para desarrollar y comercializar nanopartículas de circARN con su carga útil de ARN propietaria.
Esta colaboración marca la primera asociación para la plataforma CycloPhore recientemente lanzada de Altamira, diseñada específicamente para la entrega de ARN circular. Según la directora de operaciones, Covadonga Pañeda, el ARN mensajero circular podría permitir dosis más bajas y administraciones menos frecuentes en comparación con el ARN mensajero lineal, representando un enfoque prometedor en el desarrollo de medicamentos basados en ARN.
Altamira Therapeutics (OTCQB:CYTOF)는 원형 RNA 탑재체 전달을 위한 CycloPhore™ 플랫폼을 평가하기 위해 비공개 회사와 협력 계약을 체결했습니다. 이 파트너십은 CycloPhore 나노입자를 인체 외(in vitro) 및 인체 내(in vivo)에서 시험하는 것을 포함하며, 파트너는 독점 RNA 탑재체를 사용하는 circRNA 나노입자 개발 및 상용화를 위한 라이선스 계약 협상 옵션을 보유합니다.
이번 협력은 Altamira가 최근 출시한 CycloPhore 플랫폼의 첫 번째 파트너십으로, 원형 RNA 전달에 특화되어 있습니다. COO인 Covadonga Pañeda에 따르면, 원형 mRNA는 선형 mRNA에 비해 투여 용량을 줄이고 투여 빈도를 낮출 수 있어 RNA 약물 개발에 유망한 접근법이라고 합니다.
Altamira Therapeutics (OTCQB:CYTOF) a conclu un accord de collaboration avec une entreprise non divulguée pour évaluer sa plateforme CycloPhore™ dédiée à la délivrance de charges utiles d'ARN circulaire. Le partenariat prévoit des tests des nanoparticules CycloPhore in vitro et in vivo, avec une option pour le partenaire de négocier un accord de licence pour développer et commercialiser des nanoparticules circARN avec leur charge utile d'ARN propriétaire.
Cette collaboration représente le premier partenariat pour la plateforme CycloPhore récemment lancée par Altamira, conçue spécifiquement pour la délivrance d'ARN circulaire. Selon la COO Covadonga Pañeda, l'ARNm circulaire pourrait permettre des doses plus faibles et des administrations moins fréquentes comparé à l'ARNm linéaire, constituant une approche prometteuse dans le développement de médicaments à base d'ARN.
Altamira Therapeutics (OTCQB:CYTOF) hat eine Kooperationsvereinbarung mit einem nicht genannten Unternehmen geschlossen, um seine CycloPhore™-Plattform für die Lieferung von zirkulären RNA-Nutzlasten zu evaluieren. Die Partnerschaft umfasst Tests der CycloPhore-Nanopartikel sowohl in vitro als auch in vivo, wobei der Partner die Option hat, eine Lizenzvereinbarung für die Entwicklung und Vermarktung von circRNA-Nanopartikeln mit ihrer proprietären RNA-Nutzlast auszuhandeln.
Die Zusammenarbeit stellt die erste Partnerschaft für Altamiras kürzlich eingeführte CycloPhore-Plattform dar, die speziell für die Lieferung von zirkulärer RNA entwickelt wurde. Laut COO Covadonga Pañeda könnte zirkuläres mRNA im Vergleich zu linearem mRNA niedrigere Dosierungen und weniger häufige Verabreichungen ermöglichen und stellt somit einen vielversprechenden Ansatz in der RNA-Arzneimittelentwicklung dar.
- First collaboration agreement for CycloPhore platform, validating the technology's potential
- Partner has option to negotiate licensing agreement, potentially leading to future revenue
- Technology could enable lower dosing and less frequent drug administration
- Partner company remains undisclosed, limiting transparency
- Early-stage collaboration with no guaranteed financial terms
- No immediate revenue impact as testing phase begins
Hamilton, May 27, 2025 (GLOBE NEWSWIRE) --
- Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads
- Project collaboration partner will have option to negotiate licensing agreement
Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration agreement with an undisclosed company to evaluate the potential use of Altamira’s proprietary CycloPhore™ platform for the delivery of circular RNA payloads under development by the partner company.
Under the terms of the agreement, Altamira and its collaboration partner intend to test in vitro and in vivo the use of CycloPhore nanoparticles. The partner will, under certain conditions, have the option to negotiate with Altamira a license agreement to develop and commercialize circRNA nanoparticles with their proprietary RNA payload.
“We are very excited to enter in this first collaboration to explore the utility of our CycloPhore platform”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer. “CycloPhore was launched only recently specifically for delivery of circular RNA, which has been emerging as a highly promising approach for RNA drug development. For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA. We look forward to working with our new partner who has strong expertise in circular RNA and the ambition to develop truly life changing therapeutics.”
About CycloPhore
CycloPhore is a versatile platform for safe and effective delivery of circRNA (circular messenger ribonucleic acid) into target cells. It is based on the xPhore™ technology, comprising a patented 21-amino acid peptide that can engage any type of RNA in rapid self-assembly into a nanoparticle. The nanoparticle has a size, charge, and other physical features that allow it to escape hepatic clearance and thus to reach other target tissues than the liver. xPhore protects the RNA payload from degradation in circulation and allows for rapid cellular uptake, while enabling pH-dependent endosomal escape and cytoplasmic delivery.
About Altamira Therapeutics
Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different RNA modalities, including siRNA, mRNA and circRNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary flagship programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include but are not limited to the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2024, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What is the purpose of Altamira Therapeutics' collaboration agreement announced in May 2025?
What are the potential benefits of CYTOF's circular RNA technology?
What licensing options are included in Altamira's RNA delivery collaboration?
Who is Altamira Therapeutics' collaboration partner for the CycloPhore platform?
What is the CycloPhore platform developed by CYTOF?
